Results 171 to 180 of about 1,028,456 (338)
DNA Damage Repair Defects and Survival Outcomes for Patients With Resected Pancreatic Ductal Adenocarcinoma
, 2021 Amy Chang, Marc R. Radke, David B. Zhen, Kelsey K. Baker, Andrew L. Coveler, Kit Man Wong, Venu G. Pillarisetty, Deepti Reddi, Mary W. Redman, Elizabeth M. Swisher, E. Gabriela Chiorean +10 moreopenalex +2 more sourcesLINC01116, a hypoxia‐lncRNA marker of pathological lymphangiogenesis and poor prognosis in lung adenocarcinoma
Molecular Oncology, EarlyView.The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...Marine Gautier‐Isola, Rafael Lopes Goncalves, Marin Truchi, Caroline Lacoux, Célia Scribe, Hugo Cadis, Laetitia Guardini, Sophie Bekisz, Marius Ilié, Paul Hofman, Georges Vassaux, Bernard Mari, Roger Rezzonico +12 morewiley +1 more sourceATF4‐mediated stress response as a therapeutic vulnerability in chordoma
Molecular Oncology, EarlyView.We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...Lucia Cottone, James Dunford, Eleanor Calcutt, Vicki Gamble, Filiz Senbabaoglu Aksu, Lorena Ligammari, Georgina Wherry, Giorgia Gaeta, John C. Christianson, Adrienne M. Flanagan, Udo Oppermann, Adam P. Cribbs +11 morewiley +1 more sourceA subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy
Molecular Oncology, EarlyView.Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli +3 morewiley +1 more sourceSupplementary Material for: Prognostic Impact of DNA Repair Protein Expression in Non-Small Cell Lung Cancers Treated with Platinum-Based Chemotherapy and Subsequent Curative Lung Resection
, 2018 Junghoon Shin, K.S. Lee, K. Yoh, Hyun Jin Cho, Moon Ki Choi, Sung‐Hoon Kim, Young Jin Kim, Jin-Haeng Chung, S. Cho, Kyoungmi Kim, Sang Hoon Jheon, Ho Il Yoon, Jeong Hyun Lee, C.-T. Lee, Jong‐Sook Lee +14 moreopenalex +1 more sourcethe-alpha-fetoprotein-receptor-binding-fragment-localization-of-third-domain-interaction-sites-of-dna-repair-proteins/# [PDF]
, 2017 Gerald J. Mizejewski, G Mizejewski, G Mizejewski, G Mizejewski, G Mizejewski, S Naidu, M Peterson, B Spear, F Herve, K Rajkowski, M Martin, P Dessen, M Li, P Li, S He, G Du, G Li, G Mizejewski, G Mizejewski, A Atemezem, E Mbemba, R Marfaing, J Vaysse, M Pontet, G Mizejewski, M Li, H Li, C Li, S Zhou, G Mizejewski, G Posypanova, N Gorokhovets, V Makarov, L Savvateeva, G Posypanova, V Makarov, M Savvateeva, A Bereznikova, N Yabbarov, G Posypanova, E Vorontsov, S Obydenny, O Sharapova, N Pozdnykova, D Laurinavichyute, M Yurkova, O Sharapova, M Iurkova, S Andronova, A Fedorov, O Sharapova, N Pozdniakova, D Laurinavichiute, M Iurkova, D Carter, X He, S Munson, P Twigg, K Gernert, R Osmond, S Das, M Crouch, J Gerald, Mizejewski, G Mizejewski, J Duncan, J Reeves, T Cooke, B Friedenson, K Yoshida, Y Miki, N Lakhi, G Mizejewski, L Starita, J Parvin, Y Wang, D Cortez, P Yazdi, N Neff, J Paterson, B Henderson, B Xia, Q Sheng, K Nakanishi, A Ohashi, J Wu, R Buisson, A Dion-Cote, Y Coulombe, H Launay, N Kondo, A Takahashi, E Mori, T Noda, M O'driscoll, V Ruiz-Perez, C Woods, P Jeggo, A Smogorzewska, S Matsuoka +99 moreopenalex +1 more sourceHTLV-1 bZIP factor impairs DNA mismatch repair system [PDF]
, 2023 Maki Sakurada-Aono, Takashi Sakamoto, Masayuki Kobayashi, Yoko Takiuchi, Fumie Iwai, Kohei Tada, Hiroyuki Sasanuma, Shigeki Hirabayashi, Yasuhiro Murakawa, Kotaro Shirakawa, Chihiro Sakamoto, Keisuke Shindo, Jun‐ichirou Yasunaga, Masao Matsuoka, Yves Pommier, Shunichi Takeda, Akifumi Takaori‐Kondo +16 moreopenalex +1 more sourceDeveloping evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities
Molecular Oncology, EarlyView.The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking +43 morewiley +1 more source
